⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NUVB News
Nuvation Bio Inc.
Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
businesswire.com
NUVB
Nuvation Bio Receives Approval from Japan’s Ministry of Health, Labour and Welfare for IBTROZI TM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
businesswire.com
NUVB
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
businesswire.com
NUVB